TrialJournal of diabetes investigation2021

iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post-hoc analysis of the LixiLan JP-L trial.

Daisuke Yabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.